Who are Lumigan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aleve, Linolic Acid, Meclofenamate, Travatan, Xalatan, Cytotec.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bimatoprost.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lumigan — Competitive Intelligence Brief

Lumigan (BIMATOPROST) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin Analog [EPC]. Area: Cardiovascular.

marketed Prostaglandin Analog [EPC] Aldo-keto reductase family 1 member C3 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lumigan (BIMATOPROST). Lumigan works by increasing the outflow of fluid from the eye to reduce pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lumigan TARGET	BIMATOPROST		marketed	Prostaglandin Analog [EPC]	Aldo-keto reductase family 1 member C3	2001-01-01
Aleve	naproxen	Generic (originally Syntex)	marketed	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Linolic Acid	LINOLEIC ACID		marketed		Aldo-keto reductase family 1 member C3, Fatty acid-binding protein, adipocyte, Fatty acid-binding protein, heart
Meclofenamate	Meclofenamate	Memorial Sloan Kettering Cancer Center	marketed		Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3
Travatan	TRAVOPROST		marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	2001-01-01
Xalatan	LATANOPROST	Thea Pharma	marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	1996-01-01
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin Analog [EPC] class)

· 2 drugs in this class
Pfizer · 2 drugs in this class
Aerie Pharmaceuticals · 1 drug in this class
Thea Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lumigan — Competitive Intelligence Brief. https://druglandscape.com/ci/bimatoprost. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab